Highlights Lotus Pharmaceutical Co., Ltd.

Equities

1795

TW0001795003

End-of-day quote Taiwan S.E. Other stock markets 2024-09-12			5-day change	1st Jan Change
277.50 ^TWD	+2.59%		+4.13%	+2.02%

09-06	Lotus Pharmaceutical Board to Acquire Product Rights of Vietnamese Firm	MT
09-05	Lotus Pharmaceutical Co., Ltd. agreed to acquire Intellectual Property rights of Alpha Choay from Sanofi Vietnam Shareholding Company for $50 million.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Lotus Pharmaceutical Board to Acquire Product Rights of Vietnamese Firm	09-06	MT
Lotus Pharmaceutical Co., Ltd. agreed to acquire Intellectual Property rights of Alpha Choay from Sanofi Vietnam Shareholding Company for $50 million.	09-04	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-07	CI
Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. completed the acquisition of Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V.	07-31	CI
Lotus Pharmaceutical Co., Ltd. Announces Cash Dividend, Payable on August 30, 2024	07-18	CI
Nrx Pharmaceuticals, Inc. Receives A Notice of Termination of Exclusive, Global ? Development, Supply, Marketing & License Agreement by and Between Alvogen, Inc., Alvogen Pharma Us, Inc. and Lotus Pharmaceutical Co. Ltd	06-27	CI
Lotus International Pte. Ltd and Lotus Pharmaceutical Co., Ltd. agreed to acquire Teva Pharma Co., Ltd. from Actavis Group PTC ehf., Actavis Holding Asia BV and Actavis Dutch Holding B.V. for TWD 1.5 billion.	06-05	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-13	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01-14	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Lotus Pharmaceutical Co., Ltd. and Fuji Pharma Co., Ltd. Joint Product Receives the Approval for Lenalidomide Capsules,2.5 Mg and 5 Mg from the Japan Pmda	23-08-15	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea	23-07-31	CI
Lotus Pharmaceutical Announces Cash Distribution Payable on August 1, 2023	23-06-16	CI
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101	23-06-05	CI
Lotus Pharmaceutical Co., Ltd. Approves to Enter, Jointly with Alvogen US, into an Exclusive Agreement with NeuroRx Inc. to Develop, Manufacture and Commercialize NRX-101	23-06-03	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI
Lotus Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lotus Pharmaceutical Co., Ltd.

Equities

1795

TW0001795003

Highlights

Filters